DP
KROS icon

Diadema Partners’s Keros Therapeutics KROS Stock Holding History

Diadema Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-65,800
Closed -$671K – 117
2025
Q1 		$671K Buy
65,800
+15,400
+31% +$179K 0.17% 72
2024
Q4 		$798K Buy
+50,400
New +$2.62M 0.34% 61

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Diadema Partners's KROS Position: Q1 2025 in Review

Diadema Partners sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 63,547 shares — an estimated $738K sold.

Diadema Partners first reported a position in KROS in Q4 2024 and held it in 1 quarter. The position peaked at $1.01M in Q4 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Diadema Partners reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Diadema Partners sold 63,547 Keros Therapeutics shares in Q1 2025, an estimated $738K.
  • Diadema Partners first reported a position in Keros Therapeutics in Q4 2024 and held it in 1 quarter.
  • Diadema Partners's Keros Therapeutics position peaked at $1.01M in Q4 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.